L3VLUP
ProSign in

MDGL · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MDGLLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MDGL
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterMDGLLLY
Q3 20203 holders, $311m33 holders, $14.1bn
Q4 20202 holders, $234m29 holders, $17.3bn
Q1 20214 holders, $281m24 holders, $23.0bn
Q2 20212 holders, $67m24 holders, $27.8bn
Q3 20211 holders, $18m31 holders, $29.9bn
Q4 20211 holders, $19m31 holders, $34.7bn
Q1 20221 holders, $22m24 holders, $35.3bn
Q2 20222 holders, $21m33 holders, $42.7bn
Q3 20222 holders, $14m31 holders, $43.4bn
Q4 20224 holders, $204m31 holders, $46.6bn
Q1 20239 holders, $384m33 holders, $44.3bn
Q2 20235 holders, $589m37 holders, $59.6bn
Q3 20236 holders, $579m44 holders, $67.6bn
Q4 20235 holders, $820m45 holders, $73.6bn
Q1 20248 holders, $1.1bn41 holders, $95.3bn
Q2 20247 holders, $1.1bn43 holders, $110bn
Q3 20246 holders, $788m45 holders, $107bn
Q4 20246 holders, $1.1bn46 holders, $93.9bn
Q1 20257 holders, $1.2bn42 holders, $98.4bn
Q2 20256 holders, $961m43 holders, $93.2bn
Q3 20259 holders, $1.3bn39 holders, $86.7bn
Q4 202512 holders, $1.8bn41 holders, $123bn
Q1 202610 holders, $2.2bn39 holders, $106bn
Q2 202611 holders, $2.3bn44 holders, $132bn
MDGL

Madrigal Pharmaceuticals Inc

Holders
10
Reported value
$2.2bn
Buyers
13
Sellers
15

Breadth -2 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MDGL (1)

Farallon Capital Management LLC

Only LLY (30)

Acadian Asset Management LLC, AQR Capital Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Schonfeld Strategic Advisors LLC, Soros Fund Management LLC, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →